翰宇藥業(300199.SZ)業績快報：2019年淨虧損擴至8.72億元
格隆匯2月28日丨翰宇藥業(300199.SZ)披露2019年度業績快報，報告期內，公司營業總收入6.15億元，同比下降51.34%；營業利潤-8.81億元，同比下降175.03%；利潤總額-8.69億元，同比下降160.36%；歸屬於上市公司股東的淨利潤-8.72億元，同比下降155.91%；基本每股收益-0.94元，同比下降154.05%。報告期內，公司經營業績主要受以下因素影響：
1、在嚴格醫保控費制度下，隨着輔助用藥限制、二次議價、醫保支付方式改革等相關措施緊密推行，2019年公司國內市場受影響較為明顯，銷售收入同比下降。海外市場受全球宏觀經濟及市場競爭影響，客户肽銷售減少；部分原料藥客户的製劑產品已進入註冊申報階段，對相應原料藥產品的需求量暫時降低，未來原料藥產品的進一步放量有賴於客户製劑產品申報進展以及新客户的開發進度。
2、根據《企業會計準則第8號-資產減值》及相關會計政策規定，基於謹慎性原則，經初步測算，2019年度預計對併購甘肅成紀生物藥業有限公司形成的商譽計提減值準備3.44億元，最終數據以2019年度審計報告為準。
3、根據《關於深化審評審批制度改革鼓勵藥品醫療器械創新的意見》，公司積極開展仿製藥注射劑一致性評價工作，研發費用相應增加；此外，由於藥品開發具有周期長、風險高等特點，基於對現有政策的解讀和對未來趨勢的判斷，部分品種後續投入已不再符合公司長期利益預期及發展戰略，為優化在研品種結構，經審慎決策終止部分在研項目，該部分前期資本化支出轉為費用化支出，對公司2019年淨利潤產生影響。
報告期末，公司總資產為47.54億元，較報告期初下降16.01%；歸屬於上市公司股東的所有者權益為22.52億元，較報告期初減少33.60%；歸屬於上市公司股東的每股淨資產2.46元，較報告期初減少32.79%。歸屬於上市公司股東的所有者權益和每股淨資產下降較為明顯，主要是報告期內歸屬於上市公司股東的淨利潤虧損所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
